Nilotinib
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
The University of Hong KongSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
38 Active assets in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
Cyclophosphamide Ohio State University Comprehensive Cancer Center | Phase 2 | BBB |
Tacrolimus University of Michigan Rogel Cancer Center | Phase 2 | BB |
Imatinib The University of Hong Kong | Phase 2 | BB |
Methotrexate University of Michigan Rogel Cancer Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active
BBB
Indicative · Phase 2
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →